Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAY OTCMKTS:EDTXF NASDAQ:LQDA NASDAQ:PAVM NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsway$15.80+4.6%$13.51$7.84▼$16.25$298.65M1.3455,476 shs21,570 shsEDTXFSpectral Diagnostics$1.19-4.2%$0.81$0.32▼$1.31$340.13M0.2627,059 shs27,609 shsLQDALiquidia Technologies$26.48-1.1%$22.21$9.68▼$29.94$2.27B0.221.82 million shs65,215 shsPAVMPAVmed$0.41+3.5%$0.50$0.30▼$1.77$9.08M1.09194,244 shs14,020 shsXAIRBeyond Air$2.44+0.2%$2.79$2.02▼$13.52$12.65M0.281.15 million shs44,390 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsway-4.25%-5.03%+16.33%+37.40%+83.70%EDTXFSpectral Diagnostics-4.19%-4.81%+49.69%+84.84%+143.35%LQDALiquidia Technologies+3.00%-4.32%+3.16%+96.98%+173.30%PAVMPAVmed-4.76%-6.95%-11.05%-34.58%-77.52%XAIRBeyond Air0.00%-26.59%+4.74%-57.37%-70.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsway$15.80+4.6%$13.51$7.84▼$16.25$298.65M1.3455,476 shs21,570 shsEDTXFSpectral Diagnostics$1.19-4.2%$0.81$0.32▼$1.31$340.13M0.2627,059 shs27,609 shsLQDALiquidia Technologies$26.48-1.1%$22.21$9.68▼$29.94$2.27B0.221.82 million shs65,215 shsPAVMPAVmed$0.41+3.5%$0.50$0.30▼$1.77$9.08M1.09194,244 shs14,020 shsXAIRBeyond Air$2.44+0.2%$2.79$2.02▼$13.52$12.65M0.281.15 million shs44,390 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsway-4.25%-5.03%+16.33%+37.40%+83.70%EDTXFSpectral Diagnostics-4.19%-4.81%+49.69%+84.84%+143.35%LQDALiquidia Technologies+3.00%-4.32%+3.16%+96.98%+173.30%PAVMPAVmed-4.76%-6.95%-11.05%-34.58%-77.52%XAIRBeyond Air0.00%-26.59%+4.74%-57.37%-70.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsway 3.00Buy$18.0019.21% UpsideEDTXFSpectral Diagnostics 0.00N/AN/AN/ALQDALiquidia Technologies 3.00Buy$32.1119.95% UpsidePAVMPAVmed 3.00Buy$19.004,648.81% UpsideXAIRBeyond Air 3.50Strong Buy$11.00352.67% UpsideCurrent Analyst Ratings BreakdownLatest PAVM, EDTXF, BWAY, XAIR, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025BWAYBrainswayHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.008/21/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/15/2025LQDALiquidia TechnologiesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.008/14/2025BWAYBrainswayHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$16.00 ➝ $17.008/14/2025BWAYBrainswayNorthland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $19.008/13/2025LQDALiquidia TechnologiesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$33.00 ➝ $41.008/13/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $31.008/13/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/12/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.007/17/2025XAIRBeyond AirD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsway$46.08M6.19$0.24 per share63.22$3.31 per share4.56EDTXFSpectral Diagnostics$1.67M203.67N/AN/A($0.07) per share-17.00LQDALiquidia Technologies$19.32M119.28N/AN/A$0.91 per share29.42PAVMPAVmed$1.02M8.60N/AN/A($0.92) per share-0.43XAIRBeyond Air$4.78M2.66N/AN/A$3.32 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsway$2.92M$0.2658.0894.38N/A11.60%8.97%5.65%11/11/2025 (Estimated)EDTXFSpectral Diagnostics-$11.24M-$0.07N/A∞N/A-832.89%N/A-361.73%11/7/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.70N/AN/AN/A-732.17%-232.96%-60.81%11/12/2025 (Estimated)PAVMPAVmed$39.79M$1.160.34N/AN/A7,144.80%N/A-20.96%11/12/2025 (Estimated)XAIRBeyond Air-$46.62M-$11.93N/AN/AN/A-880.72%-232.61%-115.92%11/10/2025 (Estimated)Latest PAVM, EDTXF, BWAY, XAIR, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BWAYBrainsway$0.07$0.10+$0.03$0.10$12.34 million$12.63 million8/12/2025Q2 2025LQDALiquidia Technologies-$0.43-$0.49-$0.06-$0.49$3.90 million$8.84 million8/12/2025Q1 2026XAIRBeyond Air-$1.50-$1.53-$0.03-$1.53$1.75 million$1.76 million6/17/2025Q4 2025XAIRBeyond Air-$2.80-$1.80+$1.00-$0.09$1.39 million$1.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainswayN/AN/AN/AN/AN/AEDTXFSpectral DiagnosticsN/AN/AN/AN/AN/ALQDALiquidia TechnologiesN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainswayN/A3.513.34EDTXFSpectral DiagnosticsN/A0.120.11LQDALiquidia Technologies9.842.492.41PAVMPAVmedN/A0.520.52XAIRBeyond Air0.923.242.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsway30.11%EDTXFSpectral DiagnosticsN/ALQDALiquidia Technologies64.54%PAVMPAVmed19.93%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipBWAYBrainsway19.00%EDTXFSpectral Diagnostics1.50%LQDALiquidia Technologies26.50%PAVMPAVmed7.30%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsway12018.90 million15.31 millionNot OptionableEDTXFSpectral Diagnostics29285.82 million281.53 millionNot OptionableLQDALiquidia Technologies5086.09 million60.18 millionOptionablePAVMPAVmed9021.93 million20.33 millionOptionableXAIRBeyond Air705.23 million4.21 millionOptionablePAVM, EDTXF, BWAY, XAIR, and LQDA HeadlinesRecent News About These CompaniesBeyond Air, Inc. (NASDAQ:XAIR) Short Interest Down 29.1% in AugustSeptember 16 at 2:59 AM | americanbankingnews.comBeyond Air Announces New Warrant AgreementSeptember 11, 2025 | msn.comBeyond Air, Inc. Announces Exercise of Warrants to Raise $3.25 Million for Clinical Programs and OperationsSeptember 8, 2025 | quiverquant.comQBeyond Air Announces Exercise of Warrants for $3.25 Million of Gross ProceedsSeptember 8, 2025 | globenewswire.comNeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in AdultsSeptember 8, 2025 | markets.businessinsider.comBeyond Air subsidiary granted orphan designation for malignant glioma treatmentSeptember 3, 2025 | msn.comBeyond Air, Inc. CEO Steve Lisi to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | quiverquant.comQBeyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comBeyond Air, Inc. Expands Global LungFit® PH Distribution Network to 34 CountriesAugust 20, 2025 | quiverquant.comQBeyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in JapanAugust 20, 2025 | globenewswire.comBeyond Air price target lowered to $5 from $20 at Piper SandlerAugust 14, 2025 | msn.comBeyond Air’s Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q1 2026 Earnings Call TranscriptAugust 13, 2025 | msn.comBeyond Air Reports Strong Revenue Growth in Q1 2026August 13, 2025 | msn.comBeyond Air reports Q1 EPS ($1.53) vs. ($5.32) last yearAugust 12, 2025 | msn.comBeyond Air, Inc. (XAIR) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comBeyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue EstimatesAugust 12, 2025 | zacks.comBeyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To ExpectAugust 12, 2025 | finance.yahoo.comBeyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and WebcastJuly 25, 2025 | globenewswire.comBeyond Air stock surges after securing Premier group purchasing dealJuly 22, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePAVM, EDTXF, BWAY, XAIR, and LQDA Company DescriptionsBrainsway NASDAQ:BWAY$15.80 +0.70 (+4.64%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Spectral Diagnostics OTCMKTS:EDTXF$1.19 -0.05 (-4.19%) As of 09/15/2025 02:51 PM EasternSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.Liquidia Technologies NASDAQ:LQDA$26.48 -0.29 (-1.07%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.PAVmed NASDAQ:PAVM$0.41 +0.01 (+3.47%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Beyond Air NASDAQ:XAIR$2.44 +0.01 (+0.21%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
